Rho kinase inhibitors—a review on the physiology and clinical use in Ophthalmology

Moura-Coelho, Nuno; Ferreira, Joana Tavares; Bruxelas, Carolina; Dutra-Medeiros, Marco; Cunha, João Paulo; Proença, Rita Pinto

doi:10.1007/s00417-019-04283-5

Cited by 32 publications

(27 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The profound involvement of the RhoA/ROCK pathway in various disease processes has made ROCK a potential therapeutic target in many kinds of diseases, e.g., cardiovascular ( 37 ), neoplastic ( 38 ), and neurologic ( 39 ). Moreover, ROCK inhibitors have been used as potential therapeutic drugs for several ophthalmic diseases, including glaucoma, corneal endothelial diseases, age-related macular degeneration, and diabetic retinopathy ( 40 , 41 ). However, there are few studies that have investigated the role of Rho/ROCK signaling or that of ROCK inhibitors in GO.…”

Section: Discussionmentioning

confidence: 99%

Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves’ Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways

et al. 2021

View full text Add to dashboard Cite

Transforming growth factor-β (TGF-β)-induced differentiation of orbital fibroblasts into myofibroblasts is an important pathogenesis of Graves’ ophthalmopathy (GO) and leads to orbital tissue fibrosis. In the present study, we explored the antifibrotic effects of simvastatin and ROCK inhibitor Y-27632 in primary cultured GO orbital fibroblasts and tried to explain the molecular mechanisms behind these effects. Both simvastatin and Y-27632 inhibited TGF-β-induced α-smooth muscle actin (α-SMA) expression, which serves as a marker of fibrosis. The inhibitory effect of simvastatin on TGF-β-induced RhoA, ROCK1, and α-SMA expression could be reversed by geranylgeranyl pyrophosphate, an intermediate in the biosynthesis of cholesterol. This suggested that the mechanism of simvastatin-mediated antifibrotic effects may involve RhoA/ROCK signaling. Furthermore, simvastatin and Y-27632 suppressed TGF-β-induced phosphorylation of ERK and p38. The TGF-β-mediated α-SMA expression was suppressed by pharmacological inhibitors of p38 and ERK. These results suggested that simvastatin inhibits TGF-β-induced myofibroblast differentiation via suppression of the RhoA/ROCK/ERK and p38 MAPK signaling pathways. Thus, our study provides evidence that simvastatin and ROCK inhibitors may be potential therapeutic drugs for the prevention and treatment of orbital fibrosis in GO.

show abstract

Section: Discussionmentioning

confidence: 99%

Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves’ Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways

et al. 2021

View full text Add to dashboard Cite

show abstract

“…ROCK inhibitors are known to reduce IOP by altering TM outflow resistance with the relaxation of smooth muscle cells [ 6 , 7 ]. Besides, ROCK inhibitors are beneficial to glaucoma patients with effects that are independent of IOP: it improves the blood flow to the optic nerve head (via relaxation of vascular endothelial smooth muscle cells) and promotes axonal regeneration [ 3 , 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…ROCK molecules are ubiquitous in all cellular tissues and organs, including ocular tissues such as the cornea, trabecular meshwork (TM), iris, and retina [ 6 ]. Recently, ROCK has drawn increased clinical interest in the field of glaucoma due to the improved understanding of its role in intraocular pressure (IOP) regulation [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Genetic Risk and Phenotype Correlation of Primary Open-Angle Glaucoma Based on Rho-Kinase Gene Polymorphisms

Kim

Bak

et al. 2021

JCM

View full text Add to dashboard Cite

Rho-associated coiled-coil kinase (ROCK) signaling can affect glaucoma risk by regulating trabecular meshwork outflow. We investigated the effect of ROCK gene polymorphism on the risks of primary open-angle glaucoma (POAG) and POAG-related phenotypes including intraocular pressure (IOP) in a Korean population. A total of 24 single-nucleotide polymorphisms (SNPs) from ROCK1 and ROCK2 were selected and genotyped for 363 POAG patients and 213 healthy controls. Among the 363 POAG patients, 282 were normal-tension glaucoma (NTG, baseline IOP ≤ 21 mmHg) and 81 were high-tension glaucoma (HTG, baseline IOP > 21 mmHg). The SNPs rs288979, rs1006881, rs35996865, rs10083915, and rs11873284 in ROCK1 (tagged to each other, r2 = 1) were nominally associated with risk of HTG (OR = 0.52, p = 0.045). However, there were no SNPs that were significantly associated with the risk of NTG. In the genotype-phenotype correlation analysis, the SNPs rs2230773 and rs3771106 in ROCK2 were significantly correlated with central corneal thickness (CCT)-adjusted IOP (p = 0.024) and axial length (AXL; p = 0.024), respectively. The present data implicated the role of ROCK in POAG development, and as such, can serve as a good reference for upcoming Rho/ROCK-pathway-related studies on POAG.

show abstract

“…Therefore, ROCKs are considered to be a potential therapeutic target [ 42 ]. Since the early 2000s, several inhibitor molecules have been developed with different relative potencies and biological functions [ 44 ].…”

Section: Discussionmentioning

confidence: 99%

AR12286 Alleviates TGF-β-Related Myofibroblast Transdifferentiation and Reduces Fibrosis after Glaucoma Filtration Surgery

Cheng

Chen

et al. 2020

Molecules

View full text Add to dashboard Cite

Scar formation can cause the failure of glaucoma filtration surgery. We investigated the effect of AR12286, a selective Rho-associated kinase inhibitor, on myofibroblast transdifferentiation and intraocular pressure assessment in rabbit glaucoma filtration surgery models. Cell migration and collagen contraction were used to demonstrate the functionality of AR12286-modulated human conjunctival fibroblasts (HConFs). Polymerase chain reaction quantitative analysis was used to determine the effect of AR12286 on the production of collagen Type 1A1 and fibronectin 1. Cell migration and collagen contraction in HConFs were activated by TGF-β1. However, compared with the control group, rabbit models treated with AR12286 exhibited higher reduction in intraocular pressure after filtration surgery, and decreased collagen levels at the wound site in vivo. Therefore, increased α-SMA expression in HConFs induced by TGF-β1 could be inhibited by AR12286, and the production of Type 1A1 collagen and fibronectin 1 in TGF-β1-treated HConFs was inhibited by AR12286. Overall, the stimulation of HConFs by TGF-β1 was alleviated by AR12286, and this effect was mediated by the downregulation of TGF-β receptor-related SMAD signaling pathways. In vivo results indicated that AR12286 thus improves the outcome of filtration surgery as a result of its antifibrotic action in the bleb tissue because AR12286 inhibited the TGF-β receptor-related signaling pathway, suppressing several downstream reactions in myofibroblast transdifferentiation.

show abstract

Rho kinase inhibitors—a review on the physiology and clinical use in Ophthalmology

Cited by 32 publications

References 108 publications

Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves’ Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways

Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves’ Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways

Genetic Risk and Phenotype Correlation of Primary Open-Angle Glaucoma Based on Rho-Kinase Gene Polymorphisms

AR12286 Alleviates TGF-β-Related Myofibroblast Transdifferentiation and Reduces Fibrosis after Glaucoma Filtration Surgery

Contact Info

Product

Resources

About